THE shares of Piramal Pharma Limited were trading at ₹244.98, down ₹10.86 or 4.24 per cent on the NSE today at 12:05 p.m.

Piramal Pharma Limited reported strong financial results for the second and first half of FY25, ending September 30, 2024, with consolidated revenue growth of 17% YoY to ₹2,242 crore. This increase was largely driven by the strong performance of its CDMO (Contract Development and Manufacturing Organization) segment, which grew 24% year-over-year (y-o-y).

• Also read: Piramal Pharma’s Q2 net profit grew 4 times to ₹23 crore; turnover at ₹2,242 crore

The company’s EBITDA grew 28% YoY to ₹403 crore, improving its EBITDA margin to 18% from 16% in Q2FY24. The increase reflects strategic cost optimizations and a favorable revenue mix. Additionally, net profit after tax soared 350% year-on-year to ₹23 crore, benefiting from strong operational efficiencies and strategic initiatives.

Piramal Pharma’s CDMO business led the growth with increased demand for generic APIs and a $80 million expansion of its Lexington facilityaiming to double sterile fill-finish capacities by FY27. Meanwhile, the Complex Hospital Generics (CHG) segment recorded a 9% increase in revenue, supported by growing demand for sterile fill-finish products. inhalation anesthesia in the United States and emerging markets, as well as through the continued expansion of capabilities at Dahej and Digwal.

• Also read: Piramal Pharma to invest $80 million in Kentucky facility expansion

CEO Nandini Piramal highlighted the company’s long-term goal of achieving $2 billion in revenue and 25% EBITDA margin by FY30, leveraging plans expansion and placing greater emphasis on differentiated and specialized products.